GlassScriptPhysician profile
Derek Haight
NPI 1588028401
$77,827.33
in general payments reported to CMS, 2019-2025
29 companies · $32K in 2025
The $32K reported for 2025 was more than what 98% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $624 · 2021: $449 · 2022: $5,651 · 2023: $7,555 · 2024: $32K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Food and Beverage: $8,457 · Education: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,187.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,275.00 |
| Travel and Lodging | $11,683.86 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,250.00 |
| Food and Beverage | $8,456.64 |
| Education | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $23,590.33 | 2021-2024 | Vyrsa V1, Senza |
| Globus Medical, INC. | $22,282.91 | 2025 | Senza, Vyrsa V1 |
| Boston Scientific Corporation | $17,096.92 | 2020-2025 | Wavewriter Alpha Prime 16, General - Therapies, Intracept |
| Spinal Simplicity, LLC | $5,397.49 | 2022-2024 | Ha Minuteman G3-R |
| Interventional Pain Technologies INC. | $4,000.00 | 2023 | Vyrsa V1 |
| Relievant Medsystems, INC. | $1,309.20 | 2022-2023 | Intracept |
| Abbott Laboratories | $753.68 | 2021-2024 | Proclaim, Eterna |
| Stratus Medical, LLC | $710.76 | 2022-2023 | Nimbus |
| Mml US, INC. | $519.22 | 2024-2025 | Reactiv8 |
| Abbvie INC. | $491.79 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $458.34 | 2021-2025 | Belbuca, Xtampza |
| Biotronik Nro, INC. | $293.69 | 2025 | Prospera |
| Medtronic USA, INC. | $257.51 | 2020 | |
| Medtronic, INC. | $164.36 | 2021-2025 | Inceptiv |
| Merz Pharmaceuticals, LLC | $62.97 | 2025 | Xeomin |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $56.65 | 2020-2022 | |
| Spr Therapeutics, INC | $50.40 | 2024-2025 | Sprint Pns System |
| Vertos Medical, INC. | $46.95 | 2021-2024 | Mild Device Kit |
| Averitas Pharma INC. | $43.46 | 2023-2024 | Qutenza |
| Saluda Medical Americas, INC. | $39.05 | 2021-2024 | Evoke |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.31 | 2024-2025 | Relistor |
| Hydrocision, INC. | $26.89 | 2025 | Tenjet |
| Si-Bone, INC. | $25.88 | 2022 | |
| Inspire Medical Systems, INC. | $25.37 | 2025 | Inspire |
| Becton, Dickinson and Company | $25.00 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $17.70 | 2025 | |
| Acacia Pharma INC | $16.20 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.00 | 2023 | Seglentis |
| Axsome Therapeutics, INC. | $14.30 | 2025 | Symbravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Haight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.